NCT00002222View on ClinicalTrials.gov

A Study of Valganciclovir in the Treatment of Cytomegalovirus (CMV) Retinitis in Patients With AIDS

NACompletedINTERVENTIONAL
Enrollment

200

Participants

Timeline

Start Date

Not specified

Conditions
Cytomegalovirus RetinitisHIV Infections
Interventions
DRUG

Valganciclovir

Trial Locations (1)

10021

Cornell AIDS Clinical Trials Unit, New York

All Listed Sponsors
lead

Hoffmann-La Roche

INDUSTRY

NCT00002222 - A Study of Valganciclovir in the Treatment of Cytomegalovirus (CMV) Retinitis in Patients With AIDS | Biotech Hunter | Biotech Hunter